Morgan Joseph Reiterates a 'Buy' on Amarin (AMRN); European Guidelines Bode Well For AMR101

Article Stock Quotes (1) Comments (0)

Morgan Joseph reiterates a 'Buy' on Amarin Corporation (NASDAQ: AMRN), PT $25.

Morgan analyst says, "On Tuesday, June 28, 2011, the European Society for Cardiology (ESC) and the European Atherosclerosis Society (EAS) jointly released new guidelines for the management of dyslipidemias. In our view, these guidelines underscore the focus on managing low-density lipoprotein-associated cholesterol (LDL-cholesterol, or so-called "bad" cholesterol) and thus provide a solid rationale for the introduction of an agent like Amarin's AMR101."

For more ratings news on Amarin Corporation click here and for the rating history of Amarin Corporation click here.

Shares of Amarin Corporation closed at $14.79 yesterday, with a 52 week range of $2.02-$19.87.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
• UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
• KeyBanc Upgrades Cedar Shopping Centers (CDR) to Hold

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Morgan Joseph

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?